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Introduction:
Type 1 diabetes (T1DM) is increasing in prevalence across the globe, particularly in westernised countries with incidences of 8-17 per 100,000 people in Northern Europe and the US, and rising to 35 per 100,000 in Scandinavia 1, 2 . The disease arises following the destruction of beta cells in the pancreas, resulting from an autoimmune response, with sufferers having autoantibodies to the 65-kDa isoform of glutamic acid decarboxylase, zinc transporter proteins, phosphatase-related IA-2 molecule, insulin and islet cells 3 . While not everyone with autoantibodies will progress to T1DM, the likelihood increases with the number of autoantibodies with 3-4 antibody types increasing the risk to ~80% 3 .
There is an important need for early stage biomarkers of the disease progression in T1DM in order to better understand the early aetiology of the disease and potentially target immunosuppression therapy to prevent the further destruction of pancreatic beta cells.
Furthermore, there is significant evidence that immunomodulation by infection can be used to prevent T1DM if targeted to the right clinical window of autoimmunity 4, 5 . While autoantibodies do discriminate between type 1 diabetics and healthy individuals, autoantibodies are relatively late stage changes and do not always lead to beta cell destruction 3 , confounding their use as reliable biomarkers
Metabolomics, the study of the metabolite complement of a biofluid, cell, tissue or whole organism 6 has been previously used to follow both early and late stage changes in T1DM.
Drug induced T1DM using streptozotocin induces a variety of metabolic changes in rodents including metabolites in the citric acid cycle, glucose metabolism, choline turnover and amino acid metabolism 7 . These pathways have also been confirmed to be altered in humans with T1DM, and in particular insulin treatment has also been associated with protein turnover/amino acid metabolism and ketosis in healthy individuals in human intervention studies 8, 9 . In addition metabolomics has been used to discriminate type 1 diabetics with early stage kidney disease from those without [10] [11] [12] . However, these are late changes in the pathogenesis of T1DM and are unlikely to provide biomarkers of the pre-diabetic state.
A sub-set of the field of metabolomics is lipidomics, which studies the lipid component of biofluids, cells or tissues. Lipidomics has been transformed by recent developments in liquid 4 human sufferers with T1DM [14] [15] [16] [17] [18] . Examining serum from children who subsequently went on to develop T1DM, Oresic and colleagues 14 identified a number of early stage metabolic changes, including reduced concentrations of succinate, phosphatidylcholines and triglycerides at birth. In addition, prior to serum conversion in terms of autoantibodies, individuals had increased pro-inflammatory lysophosphocholines, and reduced concentrations of triglycerides and anti-oxidant ether lipids. Metabolic changes have even been detected in the cord blood of babies that subsequently developed T1DM before the age of 8 17 .
In the present study we have profiled metabolic and lipidomic changes in a mouse model of autoimmune diabetes. The non-obese diabetic (NOD) inbred mouse strain recapitulates the autoimmune nature of T1DM in humans and has allowed researchers to follow the autoimmune destruction of beta cells in the pancreas as well as develop treatments that halt this process 19 . The mouse develops islet infiltration (insulitis) at around 3-4 weeks comprising initially of innate immune cells such as macrophages and dendritic cells followed by T cells and other cells of the immune system 20-23 22-24 . The mice develop diabetes from around 14 weeks of age. This mouse model has been used previously to monitor metabolic changes that accompany the progression of T1DM 16 , but in this previous study only NOD mice were considered, and thus, it is difficult to determine what changes were associated with disease progression and what was associated with age-related changes in the pancreas. In the present study we have compared metabolic changes in NOD mice with their transgenic control strain NOD-E mice. The NOD-E mouse is a transgenic mouse generated directly on the NOD background which, unlike the NOD mouse, expresses the major histocompatibility complex (MHC) class II I-E heterodimer 25 . These mice are protected from the development of T1DM and develop negligible insulitis. In the present study we show by metabolomics that the NOD-E mouse is a better control for the metabolic changes associated with the NOD mouse compared with the NOD severe combined immunodeficiency (SCID) mouse strain 26 . 26 
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All mice were obtained from stable colonies housed within the Department of Pathology, University of Cambridge. The incidence of diabetes in NOD female mice in this colony is around 80%. Further details as the progression of the disease process are found in the supplementary section. Mice were housed in a temperature-and humidity-controlled facility, with a 12-h:12-h light-dark cycle and access to water and regular chow diet (Caloric content:
11.5% fat, 26.9% protein, 61.6% carbohydrate; RM1; Special Diet Services, UK) ad libitum. Two studies were performed. The first examined blood plasma and pancreatic tissue taken post mortem from stable colonies of female NOD, NOD-E and NOD-SCID mice (Supplementary Table 1 ). In the second study blood plasma was sampled at six time points (6, 9, 11, 14, 19 , and 22 weeks) for female NOD (n=9), NOD-E (n=7) and NOD-SCID mice (n=10) (Supplementary Table 2 ). In this study pancreas tissue was taken at the end of the study.
Analysis of the metabolite composition of faeces
To assess changes in the gut metabolome mouse faeces were collected from individual NOD (n=5 for 6 weeks age and n=6 each for 12 and 18 weeks age) and NOD-E mice (n=5 for 6 and 12 weeks age). 20 mg of faeces were extracted using the chloroform/methanol extraction procedure described below.
Metabolite extraction from the pancreas, blood plasma and faeces
Metabolites (50 µl plasma or 50 mg tissue wet weight) were extracted using a modified Bligh 
Lipidomics analysis of blood plasma and pancreas tissue
All solvents used were of LC-MS grade or better and ordered from Sigma Aldrich (Gillingham, UK). All internal standards were obtained from Avanti Polar Lipids (Alabaster, AL, USA) with the exception of undecanoic acid and trilaurin (Sigma Aldrich).
The samples, QC samples (pools of either the plasma and pancreas extracts) and blanks were placed in a pre-defined random order across 96-well plates (Plate+, Esslab, Hadleigh, UK). The extracts were reconstituted in 100 µl of 7.5 mM NH 4 Ac IPA:MeOH (2:1), spiked
sphingosylphosporylcholine, undecanoic acid, and trilaurin) which were used to correct for variations in m/z across the dataset acquired.
Lipidomics was performed on the extract using chip-based nanospray with an Advion TriVersa Nanomate (Advion, Ithaca, USA) interfaced to the Thermo Exactive Orbitrap Acquired spectral raw data were processed using an in-house bioinformatics platform based on XCMS 28 . This performed sample-specific mass re-calibration using predefined sets of internal standards and the removal of commonly present contaminant ions (often associated with plasticizers) with help of predefined rejection lists and mass defect filters. The raw data were converted to .mzXML (using MSconvert 29 with peakpick level 1), parsed with R and 50
(scan from 20 to 70) spectra were averaged per sample using XCMS 28 , with a signal cutoff at 2000. The files were aligned using the XCMS 28,30 grouping function using "mzClust" with a m/z-window of 22 ppm and a minimum coverage of 60 %. Isotopes were annotated using the CAMERA package in R with the following parameters (maxcharge=1, ppm=5, mzabs=0.001, intval = c("into"), minfrac=0.25)
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Automated compound annotation was carried out using both an exact mass search in compound libraries as well as applying the referenced Kendrick mass defect approach.
Signal normalisation was performed by summing the intensities of all detected metabolites to a fixed value to produce a correction factor for the efficiency of ionisation. Features of interest were subsequently confirmed using fragmentation experiments on a Thermo Velos
Orbitrap mass analyser using an Advion Nanomate to directly infuse the lipid extract or a Surveyor HPLC system for chromatographic separation. The selected masses were isolated with a 1.5 m/z width in the linear ion trap and then fragmented using either linear ion trap with 35% relative collision energy or in the HCD (higher-energy collision-induced dissociation) collision cell, with a range of collision energies from 5% to 75% relative collision energy. All spectra were recorded in the Orbitrap set at 100,000 resolution. As fragmentation data confirms the fatty acids that are present but does not definitively define where the double bonds are placed these annotations are at level 2 of the Metabolomics Standards
Initiative
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Targeted analysis of aqueous metabolites in blood plasma, pancreas and faeces
All analyses were carried out using a QTRAP 4000 quadrupole mass spectrometer (AB Total plasma fatty acid analysis using fatty acid methyl esters by Gas Chromatography -
Mass Spectrometry of blood plasma, pancreas and faeces
Total fatty acid analysis was performed as described in 34 .The organic fraction was dissolved GC-MS chromatograms were processed using Xcaliber (version 2.0; Thermo Scientific).
Each individual peak was integrated and then normalized to total intensity of the FAMEs detected. Overlapping peaks were separated using traces of single ions. Peak assignment was based on mass fragmentation patterns matched to the National Institute of Standards and Technology (USA) library and to previously reported literature. Identification of metabolites from organic phase GC-MS analysis was supported by comparison with a FAME .
Univariate statistical analysis
Univariate statistical tests including Student's t-test and ANOVA were performed with Matlab (Mathworks) using the Statistical Toolbox, with the exception of Pearson correlation plots which were performed within the statistics package R (www.r-project.com) as described in 35 .
For univariate statistics a Bonferonni correction was applied to correct for multiple testing.
Multivariate statistical analysis
The metabolic profiles obtained, containing integral information, were analysed using the multivariate statistical analysis tools found in SIMCA (version 13; Umetrics AB, Umeå, Sweden . Where relevant OPLS-DA models were further validated by selecting 2/3 of the data randomly and then predicting the class membership of the other 1/3.
Results:
Lipidomics of blood plasma:
Blood plasma from both the cross sectional study and time course study were analysed using direct infusion (DI-)MS in positive ion mode (Figure 1a) . 250 variables were detected across the dataset and these were imported into the multivariate models. Initially, the samples from the NOD, NOD-E and NOD-SCID mice were compared. OPLS-DA readily separated the three mouse genotypes according to their lipidomic profiles, regardless of age Removing the NOD-SCID group from the dataset, and comparing the NOD and NOD-E mice for those aged 4-23 weeks, OPLS-DA discriminated the two mouse strains (Figure 1d ).
NOD-E were characterised by increased concentrations of cholesterol esters and lysophosphatidylcholines ( Table 1 for list of metabolite changes) while NOD mice had higher concentrations of a range of triglycerides and diglycerides ( Table 1) Table 1) . A more robust OPLS-DA model was built for mice aged 14 weeks and older (Figure 1f) . However, the distinct pattern between cholesterol esters and lyso-phospholipids versus triglycerides found in the overall NOD compared with NOD-E mice comparison, and the younger mice was no longer apparent at this later time point ( Table 1) .
Next we compared lipidomic profiles of NOD mice aged 25-30 weeks who had not developed T1DM (NOD* group) with the NOD and NOD-E lipidomic profiles used in the previous comparisons. No model could be built that discriminated that NOD* group from the Page 10 of 37
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Using this model to classify the NOD* group, 10/10 samples were classified with the NOD-E group, with the average predicted Y = 0.84 ± 0.14, where Y=1 is a perfect classification as a NOD-E mouse and Y= 0 is a perfect classification as a NOD mouse. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Finally we examined whether we could model time changes in either the NOD or NOD-E mice using PLS to regress age of animal against metabolic profiles. A robust model was built for regressing the blood plasma profile of NOD mice against age (Figure 2d shows the actual verses predicted age of mice according to the total fatty acid profile of the blood plasma). This was caused by increases in C18:3, C18:2, and C20:4, and decreases in C16:1, cholesterol, C22:0, and C20:3 as the animals age. However, no model could be produced for the NOD-E mice that passed cross validation. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 according to genotype, with NOD-SCID mice most separated along the first component compared with the other two animal models (Figure 3a) . Similarly to the lipidomic data, a more robust model could be built separating the NOD-SCID mice from the other two strains (Figure 3b) . To test the validity of the model further, an OPLS-DA model was built using 2/3 of the data and then predicting the class membership of the remaining third. This correctly picked the classification of 92% of the data. This separation was driven by increases in trimethylamine-N-oxide, kynurenine, 1-methyl-histidine, xanthosine and lysine and decreases in cobalamin, betaine, β-hydroxyisovaleric acid, acetylcholine and inosine diphosphate in the NOD-SCID mice (Figure 3c) . Taking the metabolites with a Variable Importance Parameter >1 from this model, metabolites involved in nucleotide metabolism, Bvitamins, one-carbon metabolism/choline breakdown and amino acids were responsible for this discrimination (Supplementary Table 3 ). Using the metabolite enrichment software on MetaboAnalyst 37 the most perturbed pathways were glycine, serine and threonine metabolism, biotin/thiamine metabolism, beta-alanine metabolism, tryptophan metabolism and protein biosynthesis.
DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS DI-MS
Underlying the large differences between NOD-SCID mice and the other two strains, a weaker model was produced examining NOD and NOD-E mice, regardless of age. OPLS-DA produced a one component model with three orthogonal components with a Q 2 = 50%
indicating the separation was less marked than models involving the NOD-SCID strain (Figure 3d) . To test the validity of the model further, an OPLS-DA model was built using 2/3 of the data randomly selected and then predicting the class membership of the remaining third. This correctly picked the classification of 83% of the data. This was associated with an increase in the concentrations of argininosuccinate, cobalamin, creatinine, AMP and kynurenic acid in NOD mice and a relative increase in concentration of serotonin, 5-hydroxytryptophan (5-HT), phosphoethanolamine, phosphoenolpyruvate and ornithine in NOD-E mice (Figure 3e) . While better models could be built considering mice aged below 14 weeks (Figure 3f ) and over 14 weeks (Figure 3g) , similar metabolites drove all three models (Figure 3e & 3h) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 indole (p = 0.0003). In all three models the use of SUS plots demonstrated that the metabolic effects of ageing were similar across all three mouse groups (Figure 4b) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   20 highly correlated with the majority of metabolites, as might be expected by the major precursor to many of these metabolites (Figure 5b) . However, for both mouse strains it was not correlated to serotonin, 5-HT and 5-hydroxyindole acetic acid concentrations, unlike the metabolites in the NAD biosynthesis and xanthurenic pathways, suggesting the latter two pathways are in part regulated by the total concentration of tryptophan. For the NOD-E mice the pathway from kynurenine to xanthurenic acid was more pronounced than that found in NOD mice, while correlations were more evenly spread across metabolites including anthranilic acid and quinolinic acid for NOD mice. 
Alterations in metabolism in the pancreas using lipidomics:
Our lipidomic analysis was applied to the pancreas samples to further investigate whether 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 6a), 470 variables were detected across the dataset and these were imported into the multivariate models. Examining samples from mice regardless of age, again, the samples from the NOD, NOD-E and NOD-SCID mice were compared and OPLS-DA readily separated the three mouse genotypes according to their lipidomic profiles (Figure 6b) demonstrating the profound difference between the three mouse models. This model was improved by a two group comparison where the NOD-SCID mice were compared with a combined group of NOD and NOD-E mice (Figure 6c) To further examine the metabolic changes in the pancreas we examined NOD and NOD-E mice aged 16 weeks of age and older, comparing NOD mice that had either developed or not developed diabetes. However, no model could be built that discriminated between NOD and NOD-E mice, and a combined NOD-E, NOD and NOD non diabetic model, suggesting that metabolic differences were most apparent at the earlier time points. To confirm this, a 
Alterations in amino acid metabolism in the pancreas:
Repeating the amino acid based assay analysis for the pancreas, again the pancreas of the NOD-SCID mice were significantly different from the other two mouse models either treating all three models as distinct groups (data not shown) or comparing the NOD-SCID mice with a combined group of NOD and NOD-E mice (Figure 7a ). This was driven by increases in Similar results were produced when the data was Pareto scaled (Figure 7d ). 
Modelling correlated metabolism between blood plasma and the pancreas
To examine whether metabolic changes in the pancreas manifested themselves in blood plasma, OPLS was used to regress changes in aqueous metabolism in the pancreas against the same metabolites detected in blood plasma across 23 week old NOD, NOD-E and NOD-SCID mice. Applying this approach to all the mouse models a weak OPLS model was built (2 Page 24 of 37
ACS Paragon Plus Environment
Journal of Proteome Research   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 components and 2 orthogonal X components; R 2 (X) = 53%; R 2 (Y) = 54%; Q 2 = 8%; Figure 1b) .
Examining changes in the gut metabolome
To investigate whether changes in the mouse metabolome could be related to alterations in the gut metabolome we examined the metabolite composition of faeces from NOD and NOD-E mice using GC-MS to examine the total fatty acid compliment and LC-MS/MS to examine the aqueous metabolome. While no PLS-DA or OPLS-DA models could be built separating the spectral profiles at 6 weeks or 12 weeks of age (n=6 for both groups), a time trend was detected using PLS considering either all mice (for total fatty acids: 2 components; (Supplementary figure 2) . For the NOD mice this was driven by an increase in C14:1, C18:3n-6 and C18:3n-3 fatty acids, serotonin, guanosine, creatine and trimethylamine, and a decrease in C16:0, C18:0 and C20:0 fatty acids, ADMA, taurine, citrate and α-ketoisocaproic acid.
Discussion:
The NOD mouse and its related strains have been major research tools for understanding how T1DM arises across the natural life course of the animal 38 . The mouse develops a number of autoantibodies as it ages including those recognising autoantigens insulin, IA-2 and glutamic acid decarboxylase that, as in humans, provide markers of Page 25 of 37
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Journal of Proteome Research   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 26 ongoing beta cell destruction. The NOD mouse has been the subject of a number of previous metabolomic studies which have used the reproducible time course and incidence of T1DM in this model to follow metabolic changes that accompany the development of T1DM 16,18,39-41 . However, these studies have focussed solely on NOD mice, and thus it is difficult to disentangle any metabolic changes that are associated with ageing in the animal from the subsequent age related changes associated with the development of T1DM. To address this Fahrmann and colleagues 18 compared NOD mice that developed T1DM with those that did not across the time course. In the present study we took an alternative strategy and compared the metabolic profiles of blood plasma and pancreatic tissue from NOD, NOD-E and NOD-SCID mice, the latter two strains being protected from the development of T1DM compared with NOD mice.
We compared both lipid and aqueous metabolism changes in both blood plasma and pancreas tissue across the three mouse models, and a striking result was the discrimination of NOD-SCID mice from the NOD and NOD-E strains. In terms of both intact lipids and the core metabolic pathways measured in our aqueous assays, NOD-SCID mice were readily discriminated from the other two strains and in cross validation of the associated pattern recognition models, NOD-SCID mice could be classified with 100% success according to their metabolic profiles regardless of age. The profound metabolic differences, which discriminate the NOD-SCID mice from the other two strains indicate that this model is a poor control strain to compare with NOD mice when considering the metabolic changes that accompany T1DM. As a result we have focussed on the discrimination between NOD and NOD-E mice in terms of the metabolic changes that accompany the development of T1DM.
We focussed on female mice given the sexual dimorphism of the risk of developing T1DM.
Females mice are more likely to develop T1DM and this is thought to be due to both a sexspecific, epistatic interaction with Idd4.1 in females 42 and differential interactions with the gut microflora in male and female NOD mice 43 .
Across both lipid and aqueous metabolites datasets in both blood plasma and the pancreas we could discriminate NOD and NOD-E mice readily, and indeed in NOD mice younger than 14 weeks, and hence prior to the onset of T1DM, it was possible to discriminate mice according to their lipid and aqueous profiles from the NOD-E strain.
Examining the RIP CD154 x RAG-/-mouse, a different model for T1DM produced by expressing CD154 under the rat insulin promoter crossed into the immuno-deficient recombination-activating gene (RAG) knockout mouse, Overgaard and colleagues have also
shown that metabolic changes pre-date the development of overt T1DM. Indeed some of the metabolic changes were similar between the CD154 x RAG-/-mouse and the NOD mouse with decreases in lysophosphatidylcholines and decreased methionine (detected in the 17, 44 . However, it was not possible to discriminate between NOD mice that did not develop autoimmune diabetes from NOD-E mice at 25-30 weeks, suggesting that metabolism normalises for those NOD mice that avoid autoimmune diabetes in the normal disease aetiology.
In terms of different classes of metabolites, one of the biggest changes was associated with amino acid metabolism, both in terms of discrimination of the three strains of mice and the progression of the disease in NOD mice. Alterations in amino acid metabolism have been reported in a number of previous studies. Lu and co-workers have previously identified alterations in 5-oxoproline, glutamate and homocysteine as being common to T1DM, type 2 diabetes (T2DM) and fulminant type 1 diabetes in patients compared with a control group 45 . Deja and co-workers correlated increased concentrations of alanine and valine with increased concentrations of glycated haemoglobin (HbA1c) using 1 H NMR spectroscopy of urine 46 . Indeed, alterations in amino acid metabolism appears to be a central feature of both T2DM and other rarer forms of diabetes. Perhaps the most robust metabolic markers for predicting future T2DM incidence are branch chain amino acids, and Patel and colleagues, investigating A-β+ ketosis-prone diabetes using stable isotope techniques to follow metabolic flux noted that although sufferers had normal oxidation rates of fatty acids and acetyl-CoA, there was increased leucine oxidation, conversion of glutamine to glutamate but impaired conversion of glutamate to 2-oxoglutarate and reduced flux into the citrulline cycle 47 . In the present study blood plasma from NOD mice were characterised by increases in arginosuccinate and a reduction in ornithine, similarly indicating alterations in the citrulline cycle consistent with a reduction in urea production. The turnover of the citrulline cycle, and in particular metabolites around arginine, suggests that there may be increased NO production and could be associated with activated macrophages and subsequent pathology. Xanthine, a purine breakdown product and a precursor for uric acid, was also found to be increased in the pancreas of NOD mice. Increased purine catabolism and the induction of xanthine oxidase has previously been linked to T1DM associated diabetic nephropathy in streptozotocin-dosed rats, presumably through the generation of ROS species in the kidneys 48 . Further evidence of dysfunction in the kidneys is suggested by the increased creatinine concentrations in the blood plasma of NOD mice in the present study.
It has previously been observed that nicotinamide has the ability to both prevent T1DM in prediabetic NOD mice and reverse the pathology in mice that exhibit hyperglycemia 38 , and one of the major changes detected in both the pancreas and blood plasma in the , and alterations in this pathway have previously been detected in patients with T1DM 50 . In addition, the tryptophan pathway has been highlighted in a number of chronic diseases as well as ageing 51 .
Fahrmann and colleagues 18 previously described how changes in ROS species and their associated products accompany the development of T1DM in the NOD mouse. While we did not find changes in the production of ROS products, such as oxidized amino acids and nucleotides, in the present study a reduction in methionine was detected in the pancreas of NOD mice suggesting they may have increased oxidative stress compared with NOD-E mice.
A wide range of lipid species were altered across the three strains and across the time courses, and a number of previous studies have highlighted altered lipid metabolism both pre and post overt T1DM 8, 17, 52, 53 . Alterations in lipid metabolism in female NOD mice has previously been reported by Markle and colleagues 23 who reported alterations in sphingolipid metabolism in female NOD mice who have a higher incidence of T1DM compared with male mice. These changes could be corrected if the female mice were given a faecal transplant from male mice, indicating these changes were in part driven by the gut microflora. However, sphingolipids are not found in bacteria, suggesting the lipid changes were a downstream effect rather than something that directly acts on sphingolipid metabolism. Furthermore, Makinen and colleagues have also suggested altered sphingolipid metabolism in patients with type 1 diabetes-associated kidney disease 54 . While we did not detect changes in sphingolipid metabolism in blood plasma, there were a number of sphingolipid species altered in the pancreas -being one of the classes of lipids that most readily discriminated NOD-SCID from NOD and NOD-E mice. In addition SM(39:1) was increased in the pancreas of NOD mice and Cer (d34:1) in the pancreas of NOD-E mice.
In blood plasma, the NOD mice were clearly characterised by increases in triglycerides containing longer, polyunsaturated fatty acids, and relative decreases in lysophospholipids containing longer polyunsaturated acids as well as cholesterol esters.
Alterations in phospholipids, especially lysophospholipids, and cholesterol esters have previously been described in T1DM with well controlled diabetes compared with healthy controls 17, 52, 55, 56 , with Fievet and colleagues explaining this as arising from lipoprotein remodelling and an increased pro-inflammatory state for those with T1DM. Indeed, in children autoantibodies to a number of lysophospholipids have also been described 57 , demonstrating the interplay between this class of lipid and autoimmune disease.
Conclusions:
In summary, we have used a combination of lipidomics and metabolomics to profile the development of T1DM in the NOD mouse and compare these changes with NOD-E and NOD-SCID mice, two strains that are protected from T1DM. This approach has highlighted that the NOD-SCID mouse provides a poor control for the NOD mouse in terms of metabolic changes, and indeed the most profound metabolic differences between the mouse strains were between NOD-SCID and the other two strains, regardless of diabetic status, underlining how different the NOD-SCID mice are. When comparing the NOD and NOD-E mice the most consistent metabolic changes are in the tryptophan pathway and in particular in the synthesis of kynurenic acid derivatives, and a reduction in lysophospholipids. Both pathways have previously been implicated in modulating immune responses, underlying the interplay between metabolism and inflammation. As well as highlighting metabolic mechanisms that could be targeted to treat T1DM, such metabolic markers of disease could be used in the future to target immune-suppression therapies to reduce the likelihood of developing T1DM in at risk populations.
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